Kiniksa(KNSA) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution – ARCALYST (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth – – Conference call and webcast scheduled for 8:30 am ET today – LONDON – October 28, 2025 – Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardio ...